Advanced

Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis

Järnerot, G ; Ström, M ; Danielsson, A ; Kilander, A ; Lööf, L ; Hultcrantz, R ; Löfberg, R ; Florén, C LU ; Nilsson, A LU and Broström, O (2000) In Alimentary pharmacology & therapeutics 14(9). p.62-1159
Abstract

BACKGROUND: To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC).

METHODS: 199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 mg twice daily or placebo was added to the 5-ASA based maintenance treatment. Clinical and endoscopic follow up was performed after 1, 6 and 12 months.

RESULTS: Intention-to-treat analysis after 6 and 12 months showed similar results in both groups. A log-rank test showed that 77% in the allopurinol compared to 59% in the placebo group were still in remission after 6 months (P=0.0083) and 62% and 53% after 12 months, respectively... (More)

BACKGROUND: To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC).

METHODS: 199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 mg twice daily or placebo was added to the 5-ASA based maintenance treatment. Clinical and endoscopic follow up was performed after 1, 6 and 12 months.

RESULTS: Intention-to-treat analysis after 6 and 12 months showed similar results in both groups. A log-rank test showed that 77% in the allopurinol compared to 59% in the placebo group were still in remission after 6 months (P=0.0083) and 62% and 53% after 12 months, respectively (P=0.0936). This was mainly due to a higher than expected number of relapses during the first 3 months in the placebo group. After the first 3 months, the rate of relapse in each group was similar.

CONCLUSIONS: It appears possible that allopurinol in combination with 5-ASA is better than 5-ASA alone for a 6-month, but not a 12-month period. This has to be verified in further dose-ranging studies.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Aged, Allopurinol/administration & dosage, Anti-Inflammatory Agents, Non-Steroidal/administration & dosage, Antimetabolites/administration & dosage, Colitis, Ulcerative/drug therapy, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Mesalamine/administration & dosage, Middle Aged, Recurrence, Sweden
in
Alimentary pharmacology & therapeutics
volume
14
issue
9
pages
4 pages
publisher
Wiley-Blackwell
external identifiers
  • scopus:0033806902
  • pmid:10971232
ISSN
0269-2813
DOI
10.1046/j.1365-2036.2000.00821.x
language
English
LU publication?
no
id
df5bd628-36cf-445e-b8e0-8da03923808e
date added to LUP
2019-09-19 14:40:48
date last changed
2020-03-03 05:46:57
@article{df5bd628-36cf-445e-b8e0-8da03923808e,
  abstract     = {<p>BACKGROUND: To investigate the value of combined treatment with allopurinol and 5-aminosalicylic (5-ASA) based drugs as maintenance treatment for ulcerative colitis (UC).</p><p>METHODS: 199 patients with UC in remission but with active disease during the preceding 3 years were included. Allopurinol 100 mg twice daily or placebo was added to the 5-ASA based maintenance treatment. Clinical and endoscopic follow up was performed after 1, 6 and 12 months.</p><p>RESULTS: Intention-to-treat analysis after 6 and 12 months showed similar results in both groups. A log-rank test showed that 77% in the allopurinol compared to 59% in the placebo group were still in remission after 6 months (P=0.0083) and 62% and 53% after 12 months, respectively (P=0.0936). This was mainly due to a higher than expected number of relapses during the first 3 months in the placebo group. After the first 3 months, the rate of relapse in each group was similar.</p><p>CONCLUSIONS: It appears possible that allopurinol in combination with 5-ASA is better than 5-ASA alone for a 6-month, but not a 12-month period. This has to be verified in further dose-ranging studies.</p>},
  author       = {Järnerot, G and Ström, M and Danielsson, A and Kilander, A and Lööf, L and Hultcrantz, R and Löfberg, R and Florén, C and Nilsson, A and Broström, O},
  issn         = {0269-2813},
  language     = {eng},
  number       = {9},
  pages        = {62--1159},
  publisher    = {Wiley-Blackwell},
  series       = {Alimentary pharmacology & therapeutics},
  title        = {Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis},
  url          = {http://dx.doi.org/10.1046/j.1365-2036.2000.00821.x},
  doi          = {10.1046/j.1365-2036.2000.00821.x},
  volume       = {14},
  year         = {2000},
}